posted on 2019-08-15, 14:10authored byBarkha
J. Yadav-Samudrala, Jose M. Eltit, Richard A. Glennon
Synthetic cathinones
are, primarily, stimulant drugs of abuse that
act at monoamine transporters (e.g., the dopamine transporter or DAT)
as releasing agents or as reuptake inhibitors. In the past few years,
the emergence of >150 new synthetic cathinones has attracted considerable
attention from medical and law enforcement communities. threo-Methylphenidate (tMP), used clinically for the
treatment of ADHD and narcolepsy, is also a DAT reuptake inhibitor. tMP is somewhat structurally similar to abused cathinone
stimulants, and the structure–activity relationships (SAR)
of tMP have been well-defined. Hence, available tMP literature might assist in understanding the SAR of
synthetic cathinones, about which less is known. In the present study,
we synthesized and examined eight 2-benzoylpiperidine analogues (4, 6–12) to determine if tMP SAR might be applicable to cathinone SAR. The benzoylpiperidine
analogues were evaluated in a competition assay using live-cell imaging
against APP+ in HEK293 cells stably expressing hDAT and
in cells coexpressing DAT and voltage-gated Ca2+ channels.
All compounds were found to be DAT reuptake inhibitors, and a significant
correlation was obtained between the potency of the benzoylpiperidines
and tMP binding data (r = 0.91),
suggesting that the SAR of tMP analogues might be
directly applicable to certain synthetic cathinones as DAT reuptake
inhibitors.